154 related articles for article (PubMed ID: 17516240)
1. Oxidative inactivation of the proteasome in Alzheimer's disease.
Cecarini V; Ding Q; Keller JN
Free Radic Res; 2007 Jun; 41(6):673-80. PubMed ID: 17516240
[TBL] [Abstract][Full Text] [Related]
2. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment.
Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM
Free Radic Res; 2008 Feb; 42(2):162-70. PubMed ID: 18297609
[TBL] [Abstract][Full Text] [Related]
3. Oxidative damage in mild cognitive impairment and early Alzheimer's disease.
Lovell MA; Markesbery WR
J Neurosci Res; 2007 Nov; 85(14):3036-40. PubMed ID: 17510979
[TBL] [Abstract][Full Text] [Related]
4. Evidence of increased oxidative damage in subjects with mild cognitive impairment.
Keller JN; Schmitt FA; Scheff SW; Ding Q; Chen Q; Butterfield DA; Markesbery WR
Neurology; 2005 Apr; 64(7):1152-6. PubMed ID: 15824339
[TBL] [Abstract][Full Text] [Related]
5. Amyloid peptides in different assembly states and related effects on isolated and cellular proteasomes.
Cecarini V; Bonfili L; Amici M; Angeletti M; Keller JN; Eleuteri AM
Brain Res; 2008 May; 1209():8-18. PubMed ID: 18400214
[TBL] [Abstract][Full Text] [Related]
6. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment.
Markesbery WR; Kryscio RJ; Lovell MA; Morrow JD
Ann Neurol; 2005 Nov; 58(5):730-5. PubMed ID: 16240347
[TBL] [Abstract][Full Text] [Related]
7. The effect of CYP2E1-dependent oxidant stress on activity of proteasomes in HepG2 cells.
Kessova IG; Cederbaum AI
J Pharmacol Exp Ther; 2005 Oct; 315(1):304-12. PubMed ID: 16002458
[TBL] [Abstract][Full Text] [Related]
8. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease.
Guidi I; Galimberti D; Lonati S; Novembrino C; Bamonti F; Tiriticco M; Fenoglio C; Venturelli E; Baron P; Bresolin N; Scarpini E
Neurobiol Aging; 2006 Feb; 27(2):262-9. PubMed ID: 16399211
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment.
Mangialasche F; Polidori MC; Monastero R; Ercolani S; Camarda C; Cecchetti R; Mecocci P
Ageing Res Rev; 2009 Oct; 8(4):285-305. PubMed ID: 19376275
[TBL] [Abstract][Full Text] [Related]
10. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment.
Wang J; Markesbery WR; Lovell MA
J Neurochem; 2006 Feb; 96(3):825-32. PubMed ID: 16405502
[TBL] [Abstract][Full Text] [Related]
11. The leukocyte expression of CD36 is low in patients with Alzheimer's disease and mild cognitive impairment.
Giunta M; Rigamonti AE; Scarpini E; Galimberti D; Bonomo SM; Venturelli E; Müller EE; Cella SG
Neurobiol Aging; 2007 Apr; 28(4):515-8. PubMed ID: 16563568
[TBL] [Abstract][Full Text] [Related]
12. The 20S proteasome isolated from Alzheimer's disease brain shows post-translational modifications but unchanged proteolytic activity.
Gillardon F; Kloss A; Berg M; Neumann M; Mechtler K; Hengerer B; Dahlmann B
J Neurochem; 2007 Jun; 101(6):1483-90. PubMed ID: 17286585
[TBL] [Abstract][Full Text] [Related]
13. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease.
Greilberger J; Koidl C; Greilberger M; Lamprecht M; Schroecksnadel K; Leblhuber F; Fuchs D; Oettl K
Free Radic Res; 2008 Jul; 42(7):633-8. PubMed ID: 18654878
[TBL] [Abstract][Full Text] [Related]
14. Oxidation of thiol-proteases in the hippocampus of Alzheimer's disease.
Marcum JL; Mathenia JK; Chan R; Guttmann RP
Biochem Biophys Res Commun; 2005 Aug; 334(2):342-8. PubMed ID: 16018967
[TBL] [Abstract][Full Text] [Related]
15. Quantitative EEG in progressing vs stable mild cognitive impairment (MCI): results of a 1-year follow-up study.
Luckhaus C; Grass-Kapanke B; Blaeser I; Ihl R; Supprian T; Winterer G; Zielasek J; Brinkmeyer J
Int J Geriatr Psychiatry; 2008 Nov; 23(11):1148-55. PubMed ID: 18537220
[TBL] [Abstract][Full Text] [Related]
16. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
[TBL] [Abstract][Full Text] [Related]
17. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system.
de Vrij FM; Fischer DF; van Leeuwen FW; Hol EM
Prog Neurobiol; 2004 Dec; 74(5):249-70. PubMed ID: 15582222
[TBL] [Abstract][Full Text] [Related]
18. Increased 5S rRNA oxidation in Alzheimer's disease.
Ding Q; Zhu H; Zhang B; Soriano A; Burns R; Markesbery WR
J Alzheimers Dis; 2012; 29(1):201-9. PubMed ID: 22232003
[TBL] [Abstract][Full Text] [Related]
19. White-matter vascular lesions correlate with alpha EEG sources in mild cognitive impairment.
Babiloni C; Frisoni GB; Pievani M; Toscano L; Del Percio C; Geroldi C; Eusebi F; Miniussi C; Rossini PM
Neuropsychologia; 2008; 46(6):1707-20. PubMed ID: 18440574
[TBL] [Abstract][Full Text] [Related]
20. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients.
Hernanz A; De la Fuente M; Navarro M; Frank A
Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
